These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18923671)

  • 1. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
    Taylor WR; Thinh BN; Anh GT; Horby P; Wertheim H; Lindegardh N; de Jong MD; Stepniewska K; Hanh TT; Hien ND; Bien NM; Chau NQ; Fox A; Ngoc NM; Crusat M; Farrar JJ; White NJ; Ha NH; Lien TT; Trung NV; Day N; Binh NG
    PLoS One; 2008; 3(10):e3410. PubMed ID: 18923671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
    Chan PK; Lee N; Zaman M; Adisasmito W; Coker R; Hanshaoworakul W; Gasimov V; Oner AF; Dogan N; Tsang O; Phommasack B; Touch S; Bamgboye E; Swenson A; Toovey S; Dreyer NA
    J Infect Dis; 2012 Nov; 206(9):1359-66. PubMed ID: 22927451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
    Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
    Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
    Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
    J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidemiology, clinical picture, prevention and treatment of Avian influenza].
    Angelava NA; Angelava AV
    Georgian Med News; 2006 Feb; (131):69-76. PubMed ID: 16575138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir resistance during treatment of influenza A (H5N1) infection.
    de Jong MD; Tran TT; Truong HK; Vo MH; Smith GJ; Nguyen VC; Bach VC; Phan TQ; Do QH; Guan Y; Peiris JS; Tran TH; Farrar J
    N Engl J Med; 2005 Dec; 353(25):2667-72. PubMed ID: 16371632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H5N1 transmission and disease: observations from the frontlines.
    de Jong MD
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S54-6. PubMed ID: 18820578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
    Duwe S; Schweiger B
    J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.
    Adisasmito W; Chan PK; Lee N; Oner AF; Gasimov V; Aghayev F; Zaman M; Bamgboye E; Dogan N; Coker R; Starzyk K; Dreyer NA; Toovey S
    J Infect Dis; 2010 Oct; 202(8):1154-60. PubMed ID: 20831384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
    Hurt AC; Lowther S; Middleton D; Barr IG
    Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.